Showing 2631-2640 of 5646 results for "".
- TearClear Appoints Robert J. Dempsey Chief Executive Officerhttps://modernod.com/news/tearclear-appoints-robert-j-dempsey-chief-executive-officer/2477596/TearClear announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the only pharmaceutical company to administer preservative free eye drops to the ocular surface, that are preserved safely prior to dosing, according to a company news release. <
- FDA Quickly Authorizes Its 2nd Blood Filtering Device for COVID-19https://modernod.com/news/fda-quickly-authorizes-its-2nd-blood-filtering-device-for-covid-19/2477585/Shortly after granting an emergency authorization to Terumo BCT’s blood filtering device for COVID-19, the FDA did the same for CytoSorbents’ system, according to a FierceBiotech
- Novavax Accelerates Initiation of COVID-19 Vaccine Trial to Mid-Mayhttps://modernod.com/news/novavax-accelerates-initiation-of-covid-19-vaccine-trial-to-mid-may/2477554/Novavax announced it has identified a coronavirus vaccine candidate, NVX-CoV2373, a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’ proprietary Matrix-M adjuvant will be incorporated w
- GlaxoSmithKline Takes $250 Million Stake in Vir as Companies Pair Up to Develop Coronavirus Treatmentshttps://modernod.com/news/glaxosmithkline-takes-250-million-stake-in-vir-as-companies-pair-up-to-develop-coronavirus-treatments/2477536/GlaxoSmithKline and Vir Biotechnology announced that they have agreed to enter into a collaboration to develop anti-viral antibodies for coronaviruses, including SARS-CoV-2. In addition, to gain access to Vir’s monoclonal antibody technology, GlaxoSmithKline said it will also make an equity
- FDA Issues New Policy for Remote Ophthalmic Assessment and Monitoring Devices During COVID-19https://modernod.com/news/fda-issues-new-policy-for-remote-ophthalmic-assessment-and-monitoring-devices-during-covid-19/2477535/The FDA issued immediate guidance to help expand the capability of remote ophthalmic assessment and monitoring devices. These devices include visual acuity charts, visual field devices, general use ophthalmic cameras, and tonometers. This guidance is intended to help facilitate patient c
- Incyte, Novartis to Evaluate JAK Inhibitor Ruxolitinib for Severe COVID-19 Patientshttps://modernod.com/news/incyte-novartis-to-evaluate-jak-inhibitor-ruxolitinib-for-severe-covid-19-patients/2477527/Incyte and Novartis announced that the companies plan to initiate a phase 3 collaborative study to assess ruxolitinib plus standard-of-care, versus standard care alone, in patients suffering from COVID-19-associated cytokine storm. The clinical trial will be sponsored by Incyte in the US, where t
- FDA Launches Program to Speed Development of COVID-19 Treatmentshttps://modernod.com/news/fda-launches-program-to-speed-development-of-covid-19-treatments/2477511/The FDA unveiled a new initiative, dubbed the “Coronavirus Treatment Acceleration Programme (CTAP),” designed to expedite the development of effective treatments for patients with COVID-19. Alex Azar, secretary of the US Department of Health and Human Services, said that “as par
- Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of Inhaled Nitric Oxide Therapy for COVID-19https://modernod.com/news/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start-pilot-trial-of-inhaled-nitric-oxide-therapy-for-covid-19/2477506/Mallinckrodt and Novoteris announced that the Therapeutic Products Directorate of Health Canada has cleared the companies’ joint pilot clinical trial, entitled “Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung
- Nano Retina Announces Preliminary Results for First-in-Human Implantation of Its NR600 Artificial Retina Devicehttps://modernod.com/news/nano-retina-announces-preliminary-results-for-first-in-human-implantation-of-its-nr600-artificial-retina-device/2477482/Nano Retina, developer of the NR600, an artificial retina device that mimics the natural physiological processes of the human eye and restores functional vision to persons blinded by retinal degenerative diseases, reported preliminary results for first-in-human implantations of its artificial ret
- FDA Grants Gilead Request to Drop Orphan Drug Designation for Potential COVID-19 Treatment Remdesivirhttps://modernod.com/news/fda-grants-gilead-request-to-drop-orphan-drug-designation-for-potential-covid-19-treatment-remdesivir/2477465/The FDA on Wednesday withdrew an orphan drug designation it had granted Gilead Sciences a few days ago for its investigational antiviral remdesivir to treat COVID-19. The company, which had made the request, said it will waive all benefits that come with the designation, including an